More recently, immune checkpoint inhibitors (ICIs) antibodies targeting the PD-(L)1 axis have revolutionized cancer treatment and improved long-term survival among some patients with locally advanced and metastatic NSCLC (5, 6). Here, CD274 is linked to cancer.